Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The Attenuating Effect of Soluble Fiber Consumption on Postprandial Glycemia in Humans
NCT05349916 · View on ClinicalTrials.gov ↗
Study Summary
The main objective of the current study is to investigate whether consumption of soluble fibers (isomaltodextrin \[IMD\], partially digestible maltodextrin) and RS4 starch will lower postprandial glycemia as well as postprandial insulin in human subjects with relatively high fasting blood glucose, when consumed with a specific amount of digestible carbohydrate (rice porridge). The primary outcome of the study is the effect of fibers on postprandial blood glucose, whereas the secondary outcome will be its effect on postprandial blood insulin.
Conditions Studied
Interventions
- OTHER Control
- OTHER Isomaltodextrin Low Dose
- OTHER Isomaltodextrin High Dose
- OTHER GPC partially digestible maltodextrin
- OTHER Resistant Starch Type 4
Study Locations (1)
Indiana
- Purdue University — West Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-12-07 |
| Est. Completion | 2022-03-09 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05349916
The ClinicalTrials.gov registry entry for NCT05349916 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue University, which has 100 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Type2 Diabetes appearing as the primary indexed condition, and to 5 interventions — of which Control is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05349916 reports 1 study location spanning 1 distinct geographic area — top geographies include Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05349916 about?
NCT05349916 is a clinical study titled "The Attenuating Effect of Soluble Fiber Consumption on Postprandial Glycemia in Humans". The main objective of the current study is to investigate whether consumption of soluble fibers (isomaltodextrin \[IMD\], partially digestible maltodextrin) and RS4 starch will lower postprandial glycemia as well as postprandial insulin in human subjects with relatively high fasting blood glucose, w...
What is the current status of trial NCT05349916?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2021-12-07. Estimated completion is 2022-03-09.
What conditions does trial NCT05349916 study?
This clinical trial studies the following conditions: Type2 Diabetes, Blood Sugar; High, Postprandial Hyperglycemia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05349916?
The interventions under investigation include: Control (OTHER), Isomaltodextrin Low Dose (OTHER), Isomaltodextrin High Dose (OTHER), GPC partially digestible maltodextrin (OTHER), Resistant Starch Type 4 (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05349916?
This trial is sponsored by Purdue University, which has 100 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05349916 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.